StockData

Genmab A/S vs Vertex Pharmaceuticals

GMAB and VRTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How GMAB and VRTX compare

Vertex Pharmaceuticals scores higher on the StockData Score (15 against 0 for Genmab A/S), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricGMABVRTX
Size and price
Market cap–$137B
Share price$51.37$538.60
Change, 1 year68.6%24.0%
Change, 5 years23.9%195%
Beta (5Y)0.730.52
Employees3,029600K
StockData Score
Total score015 (better)
Valuation score00
Growth score03 (better)
Performance score06 (better)
Health score06 (better)
Dividend score00
Valuation
P/E–31.4×
P/S–10.8×
P/B–6.7×
EV/EBITDA–25.7×
P/FCF–36.0×
PEG–5.12
FCF yield–2.8%
Fair value–$426.36
Margin of safety–−26.3%
Growth
Revenue growth (TTM)–10.2%
Revenue growth, 5Y average–14.1%
Net income growth (TTM)–21.1%
EPS growth (TTM)–22.4%
EPS growth, 5Y average–8.3%
Profitability
Gross margin–86.0%
Operating margin–38.0%
Net margin–35.0%
FCF margin–30.2%
Return on equity–23.5%
Return on invested capital–34.4%
Financial health
Debt / equity–0.00
Current ratio–3.19
Altman Z-score–13.63
Piotroski F-score–7
Dividends and buybacks
Buyback yield–1.5%
Shareholder yield–1.5%
Ownership
Held by institutions79.5%95.6%
Held by insiders0.00%0.22%
Insider net buying, 12 months–−$131M
Superinvestors holding–1
Short interest, % of float–1.9%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.